

23. The method of claim 22, wherein the disease treated is autoimmune disease.
24. The method of claim 22, wherein the disease treated is inflammatory disease.
- A2
cml
25. The method of claim 21, wherein the TNF receptor is TNF Binding Protein-1.
26. The method of claim 25, wherein the disease treated is autoimmune disease.
27. The method of claim 25, wherein the disease treated is inflammatory disease.
28. The method of claim 21, wherein the disease treated is autoimmune disease.
29. The method of claim 21, wherein the disease treated is inflammatory disease.--

REMARKS

The claims in this application have been amended to appropriate condition for consideration and allowance.

The early examination and allowance of this application is respectfully solicited.

EXPRESS MAIL CERTIFICATE

Respectfully submitted,

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail to Addressee (mail label #EL583743475US) in an envelope addressed to: Commissioner of Patents and Trademarks, Washington, D.C. 20231, on October 13, 2000:

Dorothy Jenkins

Name of Person Mailing Correspondence

Dorothy Jenkins

Signature

October 13, 2000

Date of Signature

EAM:mzl:mgs

Edward A. Meilman

Edward A. Meilman

Registration No.: 24,735

OSTROLENK, FABER, GERB & SOFFEN, LLP

1180 Avenue of the Americas

New York, New York 10036-8403

Telephone: (212) 382-0700